ACCOAST: More bleeds, no benefit, with early prasugrel in NSTE-ACS

Starting patients on the faster-acting, more potent antiplatelet at the time of diagnosis, rather than at the time of the procedure, proved unsafe and ineffective in this trial.

Source: theHeart.org - September 1, 2013 Category: Cardiology Source Type: news